Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Pojavnost benzodiazepinov v skupini novih psihoaktivnih snovi v Evropi med leti 2008 in 2024
Authors:ID Majar, Katja (Author)
ID Sollner Dolenc, Marija (Author)
Files:.pdf PDF - Presentation file, download (705,08 KB)
MD5: 98A734B0483E154901C0668A40C17747
 
Language:Slovenian
Typology:1.01 - Original Scientific Article
Organization:Logo SFD - Slovenian Pharmaceutical Society
Abstract:Nove psihoaktivne snovi so sintetične ali naravne snovi, ki posnemajo učinke prepovedanih drog, a zaradi hitro spreminjajoče se sestave ostajajo nenadzorovane. Mednje sodijo tudi benzodiazepini, pomembna skupina zdravil, ki se v obliki novih analogov pojavljajo kot nove psihoaktivne snovi. Članek prikazuje pojavnost, uporabo in zdravstvena tveganja benzodiazepinov kot psihoaktivne nove snovi v Evropi med 2008 in 2024 na podlagi Evropske zbirke podatkov o novih drogah. Identificiranih je bilo 38 novih benzodiazepinov, največ (24) med leti 2014 in 2018, nato je število upadlo. Največ prijav prihaja iz Švedske, sledijo Nemčija in druge skandinavske države. Slovenija je med vodilnimi: zaznani so bili trije novi benzodiazepini in skupaj 14 različnih (37 % vseh), od katerih jih je osem v skupini I prepovedanih snovi. Večina zasegov vključuje tablete in praške, pogosto v kombinacijah, kar povečuje tveganje smrti. Leta 2020 so bili prisotni v polovici smrtnih primerov zaradi drog v Sloveniji, delež pa upada. Zloraba njihovih analogov kot novih psiho aktivnih snovi povzroča resne posledice, zato je spremljanje nujno.
Keywords:Agencija Evropske unije za droge, benzodiazepini, nove psihoaktivne snovi, zloraba
Publication status:Published
Publication version:Version of Record
Publication date:01.03.2026
Year of publishing:2026
Number of pages:str. 3-12
Numbering:Letn. 77, št. 1
PID:20.500.12556/DiRROS-31034 New window
UDC:615.214
ISSN on article:2536-4316
COBISS.SI-ID:273089027 New window
Note:Opis vira z dne 26. 3. 2026; Nasl. z nasl. zaslona;
Publication date in DiRROS:10.07.2026
Views:168
Downloads:56
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Farmacevtski vestnik : strokovno glasilo slovenske farmacije
Publisher:Slovensko farmacevtsko društvo
ISSN:2536-4316
COBISS.SI-ID:288686336 New window

Licences

License:CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:http://creativecommons.org/licenses/by-nc/4.0/
Description:A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.
Licensing start date:01.01.2025

Secondary language

Language:English
Title:The prevalence of benzodiazepines in the group of new psychoactive substances in Europe between 2008 and 2024
Abstract:New psychoactive substances are synthetic or natural substances that mimic the effects of illicit drugs but remain uncontrolled due to rapidly changing composition. These include benzodiazepines, an important group of medicines that appear as new psychoactive substances in the form of new analogues. This article presents the prevalence, use, and health risks of benzodiazepines as new psychoactive substances in Europe between 2008 and 2024, based on the European Database on New Drugs. In total, 38 new benzodiazepines were identified, most (24) between 2014 and 2018, followed by a decline. Most reports originate from Sweden, followed by Germany and other Scandinavian countries. Slovenia is among the leading countries: three new benzodiazepines were detected and 14 different ones in total (37% of all), eight of which are classified in Group I of prohibited substances. Most seizures involve tablets and powders, often in combinations, increasing the risk of death. In 2020, they were present in half of Slovenia’s drug-related deaths, though the proportion is decreasing. Monitoring remains essential.
Keywords:abuse, benzodiazepines, European Union Drugs Agency, new psychoactive substances


Back